Lyra Therapeutics (LYRA) Other Working Capital Changes (2019 - 2025)

Lyra Therapeutics has reported Other Working Capital Changes for 7 years, with the latest figure at -$1.1 million in Q4 2025.

• On a quarterly basis, Other Working Capital Changes fell 18.64% year-over-year to -$1.1 million in Q4 2025; TTM through Dec 2025 was -$4.1 million, a 21.89% decrease from a year earlier, with the FY2025 full-year figure at -$4.1 million, down 21.89% from the prior year.
• Other Working Capital Changes was -$1.1 million for Q4 2025 at Lyra Therapeutics, down from -$1.1 million in the prior quarter.
• The five-year high for Other Working Capital Changes was $4.5 million in Q1 2022, with the low at -$4.8 million in Q4 2023.
• Average Other Working Capital Changes over 5 years is -$7666.7, with a median of -$183000.0 recorded in 2025.
• The sharpest annual moves came in 2023 and 2024: Other Working Capital Changes soared 3575.0% in 2023, then sank 453.96% in 2024.
• Over 5 years, Other Working Capital Changes stood at -$2.4 million in 2021, then jumped by 164.54% to $1.6 million in 2022, then slumped by 122.5% to -$351000.0 in 2023, then plunged by 168.95% to -$944000.0 in 2024, then retreated by 18.64% to -$1.1 million in 2025.
• The last three Other Working Capital Changes figures came in at -$1.1 million (Q4 2025), -$1.1 million (Q3 2025), and -$878000.0 (Q2 2025), per Business Quant data.